Cell and Gene Therapy Access Model
Published November 4, 2026 · Coverage October 25–31, 2026, Pacific · Lower priority
CMS said October 27 that it plans to broaden its voluntary Cell and Gene Therapy Access Model beyond its initial sickle-cell focus. The agency expects to release a request for manufacturer applications in the coming months and describes negotiating outcomes-based agreements on behalf of participating state Medicaid programs.
Review qualification: The planned expansion is voluntary and prospective; no completed application process or agreement is asserted.
Applicability and suggested action: State Medicaid, specialty pharmacy and payer contracting teams can monitor the future manufacturer application and participation terms and assess potential relevance; no agreement or coverage expansion for additional therapies is established by the announcement.
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Medicare & Medicaid Sweep report →